ArticleClinical and experimental medicine2025

PDCD1 as a targetable immune checkpoint hub: therapeutic insights for ibrutinib-resistant CLL management.

Niloufar Sadat Kalaki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.